Determinants of Rapamycin Sensitivity in Breast Cancer Cells

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1013-1023

  Noh, Woo Chul ^a   Mondesire, Wallace H ^b   Peng, Junying ^b   Jian, Weiguo ^b   Zhang, Haixia ^b   Dong, JinJiang ^b   Mills, Gordon B ^b   Hung, Mien Chie ^b   Meric Bernstam, Funda ^b  

^a Korea Cancer Center Hospital   (South Korea)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P70; RAPAMYCIN; RAPAMYCIN DERIVATIVE; S6 KINASE; SMALL INTERFERING RNA; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME 10; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE MARKER; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EVALUATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MAMMAL CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, DOMINANT; HUMANS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS;

EID: 1042267229     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0043     Document Type: Article

References (48)

1. Hidalgo, M., and Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19: 6680-6686, 2000.
2. Mills, G. B., Lu, Y., and Kohn, E. C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 98: 10031-10033, 2001.
3. Garber, K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl. Cancer Inst. (Bethesda), 93: 1517-1519, 2001.
4. Hidalgo, M., Rowinsky, E., Erlichman, C., Drengler, R., Marshall, B., Adjei, A., et al. Phase 1 pharmacological study of CCI-779, a cell cycle inhibitor. Clin. Cancer Res., 6 (Suppl.): 4548s, 2000.
5. Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Piccart, M., Hess, D., et al. Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 22: 193, 2003.
6. Meric, F., and Hunt, K. K. Translation initiation in cancer: a novel target for therapy. Mol. Cancer Ther., 1: 971-979, 2002.
7. Clemens, M. J., and Bommer, U. A. Translational control: the cancer connection. Int. J. Biochem. Cell Biol., 31: 1-23, 1999.
8. Dufner, A., Andjelkovic, M., Burgering, B. M., Hemmings, B. A., and Thomas, G. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol. Cell. Biol., 19: 4525-4534, 1999.
9. Peterson, R. T., Desai, B. N., Hardwick, J. S., and Schreiber, S. L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin-associated protein. Proc. Natl. Acad. Sci. USA, 96: 4438-4442, 1999.
10. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J., 16: 3693-3704, 1997.
11. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.
12. Reynolds, T. H. T., Bodine, S. C., and Lawrence, J. C., Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J. Biol. Chem., 277: 17657-17662, 2002.
13. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4: 648-657, 2002.
14. Weng, Q. P., Kozlowski, M., Belham, C., Zhang, A., Comb, M. J., and Avruch, J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J. Biol. Chem., 273: 16621-16629, 1998.
15. Weng, Q. P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., and Avruch, J. Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 5744-5748, 1995.
16. Mills, G. B., Lu, Y., Fang, X., Wang, H., Eder, A., Mao, M., et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin. Oncol., 28: 125-141, 2001.
17. Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H., et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet., 6: 1383-1387, 1997.
18. Rhei, E., Kang, L., Bogomolniy, F., Federici, M. G., Borgen, P. I., and Boyd, J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res., 57: 3657-3659, 1997.
19. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Wash. DC), 275: 1943-1947, 1997.
20. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA, 98: 10314-10319, 2001.
21. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA, 98: 10320-10325, 2001.
22. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer, 8: 249-258, 2001.
23. Zhou, B. P., Hu, M. C., Miller, S. A., Yu, Z., Xia, W., Lin, S. Y., et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem., 275: 8027-8031, 2000.
24. De Benedetti, A., and Harris, A. L. eIF4E expression in tumors: its possible role in progression of malignancies. Int. J. Biochem. Cell Biol., 31: 59-72, 1999.
25. McKendrick, L., Pain, V. M., and Morley, S. J. Translation initiation factor 4E. Int. J. Biochem. Cell Biol., 31: 31-35, 1999.
26. Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L., et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. (Bethesda), 92: 1252-1259, 2000.
27. Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J. Biol. Chem., 277: 13907-13917, 2002.
28. Shi, Y., Gera, J., Hu, L., Hsu, J. H., Bookstein, R., Li, W., et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res., 62: 5027-5034, 2002.
29. Meric, F., Hung, M. C., Hortobagyi, G. N., and Hunt, K. K. HER2/neu in the management of invasive breast cancer. J. Am. Coll. Surg., 194: 488-501, 2002.
30. Hermanto, U., Zong, C. S., and Wang, L. H. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene, 20: 7551-7562, 2001.
31. Hyman, E., Kauraniemi, P., Hautaniemi, S., Wolf, M., Mousses, S., Rozenblum, E., et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res., 62: 6240-6245, 2002.
32. Barlund, M., Monni, O., Kononen, J., Cornelison, R., Torhorst, J., Sauter, G., et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res., 60: 5340-5344, 2000.
33. Wu, G. J., Sinclair, C. S., Paape, J., Ingle, J. N., Roche, P. C., James, C. D., et al. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res., 60: 5371-5375, 2000.
34. Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., and Chen, J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (Wash. DC), 294: 1942-1945, 2001.
35. Chen, Y., Zheng, Y., and Foster, D. A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene, 22: 3937-3942, 2003.
36. Boulay, A., Zumstein-Mecker, S., Beuvink, I., Zilbermann, F., Stephan, C., Haller, R., et al. Prolonged effect of the rapamycin derivative RAD001 on p70S6 kinase activity in tumors, skin and peripheral blood lymphocytes derived from a syngeneic rat pancreatic tumor model; correlation with efficacy of intermittent dosing schedules. Proc. Annu. Meet. Am. Assoc. Cancer Res., 43: 602, 2002.
37. Peralba, J. M., DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res., 9: 2887-2892, 2003.
38. Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res., 7: 1759-1764, 2001.
39. Stolovich, M., Tang, H., Hornstein, E., Levy, G., Cohen, R., Bae, S. S., et al. Transduction of growth or mitogenic: signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol., 22: 8101-8113, 2002.
40. Nanbru, C., Lafon, I., Audigier, S., Gensac, M. C., Vagner, S., Huez, G., et al. Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site. J. Biol. Chem., 272: 32061-32066, 1997.
41. Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivieres, S., Mercep, L., and Ferrari, S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.
42. Hosoi, H., Dilling, M. B., Liu, L. N., Danks, M. K., Shikata, T., Sekulic, A., et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol. Pharmacol., 54: 815-824, 1998.
43. Kawamata, S., Sakaida, H., Hori, T., Maeda, M., and Uchiyama, T. The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood, 91: 561-569, 1998.
44. Huang, S., Liu, L. N., Hosoi, H., Dilling, M. B., Shikata, T., and Houghton, P. J. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res., 61: 3373-3381, 2001.
45. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.
46. Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., and Mills, G. B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res., 55: 1982-1988, 1995.
47. Geoerger, B., Kerr, K., Tang, C. B., Fung, K. M., Powell, B., Sutton, L. N., et al. Antitumor activity of the rapamycin analogue CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res., 61: 1527-1532, 2001.
48. Grunwald, V., DeGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B., and Hidalgo, M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res., 62: 6141-6145, 2002.